|
Volumn 30, Issue 4, 2007, Pages 1027-1032
|
Diabetic neuropathy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
ALENDRONIC ACID;
ALGINIC ACID;
ARTEMISIA DRACUNCULUS EXTRACT;
ATORVASTATIN;
CILOSTAZOL;
CLOPIDOGREL;
DULOXETINE;
HEMOGLOBIN A1C;
HERBACEOUS AGENT;
METFORMIN;
PLANT EXTRACT;
RAMIPRIL;
RANIRESTAT;
SIMVASTATIN;
TOPIRAMATE;
TUMOR NECROSIS FACTOR ANTIBODY;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
ZINC FINGER PROTEIN;
ABSENCE OF SIDE EFFECTS;
ARTERY DISEASE;
ATHEROSCLEROSIS;
CARDIOVASCULAR RISK;
CLAUDICATION;
CLINICAL FEATURE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DIABETIC FOOT;
DIABETIC NEUROPATHY;
DRUG DOSE INCREASE;
DRUG MECHANISM;
HEART RATE;
HUMAN;
INSULIN DEPENDENT DIABETES MELLITUS;
LEG ULCER;
METATARSALGIA;
NERVE INJURY;
NONHUMAN;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SURGICAL TECHNIQUE;
ANIMALS;
DIABETIC NEUROPATHIES;
DISEASE MODELS, ANIMAL;
EDUCATION, MEDICAL, CONTINUING;
HUMANS;
PERIPHERAL NERVOUS SYSTEM DISEASES;
|
EID: 34147119739
PISSN: 01495992
EISSN: 01495992
Source Type: Journal
DOI: 10.2337/dc07-zb04 Document Type: Note |
Times cited : (19)
|
References (8)
|